When New Drug Success or Failure Gets Real-Time Odds: Kalshi Brings Prediction Markets Into Clinical Trials

Whether a new drug can clear clinical trials and regulatory review can reshape patients’ treatment options and may also change a company’s fortunes overnight. U.S. event contract trading platform Kalshi is now turning these highly uncertain outcomes into tradable contracts, partnering with public information provider AppliedXL to launch a biotech prediction market pilot program covering late-stage clinical trials and regulatory decisions by the U.S. Food and Drug Administration (FDA).

The initial contracts include AriBio’s AR1001 for the treatment of early Alzheimer’s disease, asking whether the POLARIS-AD Phase 3 trial will meet its primary endpoint. Another tracks whether the FDA will approve anito-cel, developed by Gilead and Arcellx for relapsed or refractory multiple myeloma. Reuters reported that when the program launched, there were already more than a dozen contracts on FDA decisions, including one involving Summit Therapeutics’ ivonescimab.

The prices of these contracts reflect the levels at which traders are willing to buy and sell positions on whether an event “will” or “will not” occur, thereby creating an implied probability that changes with trading. Unlike holding shares in a biotech company, event contracts can narrow the focus to a single trial endpoint or approval decision. However, prices are also affected by liquidity, the number of participants, market sentiment, and contract design, and cannot be regarded as a pure measure of a drug’s scientific value.

To reduce disputes after the fact, each contract specifies in advance the criteria and public documents used to determine the outcome, such as the primary endpoint registered on ClinicalTrials.gov, an FDA approval letter, or an advisory committee voting record. AppliedXL is responsible for monitoring data, compiling evidence, and providing an independent assessment. Automated tools may assist with document classification and information extraction, but human review is still required. The final settlement decision is made by Kalshi, the exchange operator.

The pilot is deliberately limited to late-stage studies, and clinical trial contracts are, in principle, listed only after enrollment has been completed, to reduce the possibility that public prices could interfere with patient recruitment or physician referrals. Kalshi also requires participants to verify their employment information and prohibits trading by people who possess material nonpublic information or are able to influence the outcome. However, AppliedXL also acknowledges that employment verification cannot identify every pathway through which information may be obtained via consulting work, vendors, or personal relationships.

A more fundamental issue is that an easily read probability may be given too much meaning. A clinical trial reaching a statistical endpoint does not mean the efficacy has sufficient clinical value; success in a trial also does not guarantee FDA approval. The organizers therefore emphasize that market prices are not clinical evidence, scientific consensus, or treatment recommendations, and should not serve as a basis for patients deciding whether to join or withdraw from a trial.

Whether the program can produce signals more reliable than existing analyses still depends on trading volume, the composition of participants, contract wording, and the completeness of public data. What has been announced so far is a limited pilot, with no performance record yet demonstrating its predictive accuracy. What it is truly testing is not only whether the market can correctly predict the success or failure of new drugs, but also whether a financial trading mechanism can add a publicly testable layer of expectations to the biotech industry without harming research integrity or patients’ interests.